RTTNews | Jan 17, 2022 07:38AM EST

07:37 Monday, January 17, 2022 (RTTNews.com) - Paladin Labs Inc., a unit of Endo International plc (ENDP), said Xydalba (dalbavancin for injection), a 30-minute intravenous therapy for acute bacterial skin and skin structure infections that can be administered as a single- or two-dose regimen, is now available to patients nationwide in Canada.

In April 2021, ADVANZ PHARMA Corp. and Endo announced that Endo subsidiary Endo Ventures Limited had entered into a definitive agreement with Correvio International Srl, a subsidiary of ADVANZ PHARMA, to commercialize Xydalba in Canada on an exclusive basis.

Read the original article on RTTNews ( https://www.rttnews.com/3255357/paladin-labs-launches-xydalba-in-canada-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved